The first Alzheimer's-related changes begin to develop some 25 years before memory and thinking problems appear, according to a new study that may offer a valuable guide for companies looking to test new treatments in people at an earlier stage.
The study, published on Wednesday in the New England Journal of Medicine, offers a timeline of changes in spinal fluid, brain size, the appearance of brain plaques and other factors that precede the onset of Alzheimer's in people who are genetically predestined to develop the brain-wasting disease.
"It's really the first report that we have in living people of these changes," said Dr. Randall Bateman of Washington University School of Medicine in St. Louis, Missouri who helped lead the study.
Current drugs for Alzheimer's only treat symptoms and none have yet been able to keep the fatal disease from progressing. Some researchers think that may be because the disease has been studied too late in its progression.
So scientists have been searching for ways to test treatments at an earlier stage, when many researchers think new therapies will have the best shot at doing some good.
Conducting such trials in people with the common form of Alzheimer's disease would need to be huge and last for decades.
Instead, the study by the team at Washington University focuses on families enrolled in the Dominantly Inherited Alzheimer's Network, a consortium that enrolls people who are genetically predisposed to develop the disease at an early age.
"On average, patients with this form get Alzheimer's Disease by 45," Bateman said in a telephone interview.
People in these families have a 50 percent chance of inheriting one of three genes that cause early Alzheimer's and most develop symptoms around the same time as their affected parent.
Bateman followed the progress of 129 individuals and used family histories to estimate when study subjects should begin to develop Alzheimer's symptoms. They developed a timeline of changes in the body leading up to the memory loss and declines in thinking skills associated with Alzheimer's.
The first of these changes, a drop in the level of a protein known as amyloid, can be detected in spinal fluid as early as 25 years before the disease is expected to develop.
At 15 years before onset of the disease, clumps of an Alzheimer's-related protein called beta amyloid become visible on brain scans. Other scans show shrinkage of brain structures, and levels of a toxic protein called tau start to rise in spinal fluid.
At 10 years before onset, the brain becomes less adept at using glucose and some slippage in certain kinds of memory skills can be detected.
Bateman said it is not clear whether the same timeline would apply to patients who have more common late-onset Alzheimer's disease, which usually develops after age 65. But he said the biomarkers are very similar to changes already used by doctors to characterize and track the disease.
"What we don't know is if the time, the order of magnitude and the size of these changes is similar or not," Bateman said. "It may be many years before we have this information."
Researchers plan to use information from the study to test drugs on these patients before symptoms develop.
Crenezumab, an experimental Alzheimer drug made by Roche's Genentech unit has already been selected for a similar kind of test in a large family of people in Colombia who develop early onset Alzheimer's disease.
While Bateman would not say which drugs will be tested in the study, he said they will likely test three compounds "that we think represent some of the best and most advanced compounds in development."
Results of two of the most advanced drugs being studied are expected this fall. They include late-stage studies of bapineuzumab being developed by Pfizer and Johnson & Johnson, and solanezumab, being developed by Eli Lilly .
Another drug in late-stage trials is intravenous immunoglobulin, an immune system treatment being studied by Baxter International Inc.
As many as five million Americans have Alzheimer's and the clock is ticking to find a cure.
Experts predict that without an effective treatment, the number of Americans with Alzheimer's will double by 2050 to more than 10 million, and related healthcare costs could soar to over $1 trillion a year.
"We are hopeful and grateful to God and to the medical team that they are showing signs of improvement," Liberia's Information Minister Lewis Brown told a press conference on Tuesday.
The decision came as the Ivorian national football team is due to face Sierra Leone, one of the countries that had been hard hit by the Ebola outbreak, next month in Abidjan as part of the Africa Cup of Nations 2015 qualifiers.
Infant products are particularly vulnerable to food safety scares in China after powdered milk tainted with the industrial chemical melamine led to the deaths of at least six infants in 2008
Countries that do not have Ebola cases must strengthen their capacity to detect and contain any cases immediately, the WHO said
At least twenty patients broke out of quarantine in the Liberian capital after protesters looted a medical clinic.
At the end of last year, 13,254 tonnes of spent fuel was being held in temporary storage at nuclear plants, according to data from the commission, mostly in water tanks but some in concrete containers.
The 35-year-old Nigerian woman was en route to India on a treatment tour from advanced cancer.
Doctors Without Borders International President Joanne Liu said it will take six months to bring the Ebola virus under control in West Africa.
The death toll from the world's worst outbreak of Ebola stood on Wednesday at 1,069 from 1,975 confirmed, probable and suspected cases, the agency said
Chinese scientists said Tibetan glaciers had shrunk 15 percent - around 8,000 square km (3,100 square miles) - over the past 30 years.
The A.U. "is committed to ensuring that measures are put in place to prevent the further spread of the epidemic and that adequate support is provided to affected communities," the pan-African body said in a statement.
The Canadian government will donate between 800 to 1,000 doses of the vaccine, with the final number given dependent on how much Canada holds back for research and clinical trials
The government only asked SSI to investigate a possible outbreak on June 26 and it took more than a month to find the source
An experimental Ebola drug called ZMapp, made by U.S. biotech company Mapp Biopharmaceutical, was given to two American health workers infected with Ebola in Liberia.